Introduction
interstitium which may contribute to the development of glomerulosclerosis [1, 2] . The benefits of reducing The activity of the Renin-Angiotensin System (RAS ) RAS activity in patients with diabetic nephropathy may contribute to progression of renal diseases as a and non-diabetic renal disease have been demonstrated result of its effect on arterial blood pressure and in prospective trials in which angiotensin-I-converting intraglomerular pressure. In addition, there is evidence enzyme inhibitors (ACEI ) were shown to have a that RAS may also act via non-haemodynamic mechrenoprotective effect greater than that afforded by anisms such as mesangial cell mitogenesis and by strict blood pressure control alone [3, 4] . With the influencing the balance of accumulation and degradaintroduction of angiotensin II receptor antagonists (AT 1 -ra), there is now a choice as to the method of between ACEI and AT 1 -ra [5] [6] [7] . We would like to ate with the degree of attenuation of GFR reduction. Increased bradykinin levels may also have important add to the debate regarding the merits, or otherwise, of these drugs in clinical practice and highlight the non-haemodynamic benefits by increasing the activity of metalloprotinases which degrade extracellular potential role of molecular biology in future clinical decision making.
matrix. In addition to actions on AT 1 receptors, AII also stimulates AT 2 receptors. It may be premature to
Limitations of ACE inhibition
speculate on the importance of AT 2 receptor stimulation as their clinical role in healthy humans and disease states has not been fully elucidated. In healthy humans ACE is not specific to the RAS and is involved in the breakdown of several other products, such as brady-AT 2 receptor expression in the kidney appears to be low. Stimulation of these receptors does, however, kinin. Elevated levels of bradykinin is probably the mechanism for the ACEI-related side effects such as appear to have an effect of lowering blood pressure (possibly by a central mechanism involving reduction cough and anaphalactoid reactions [8] . Cough occurs no more frequently with AT 1 -ra than with placebo [9] . in sympathetic nervous system activity) which may contribute to the antihypertensive effect of AT 1 -ra. While ACE is the principal method by which angiotensin I (AI ) is converted to angiotensin II (AII ), This dual antihypertensive action may limit the dose of AT 1 -ra such that maximally tolerated doses (as this step can also be carried out by other enzymes. Non-ACE formation of AII is not blocked by ACEI judged by blood pressure response) may be below the doses required to produce additional renoprotection and may be important in maintaining tissue AII levels. In the heart, for example, cardiac chymase activity (resulting from blockade of the 'local' RAS ). Within the kidney AT 2 stimulation has an antinatriuretic effect contributes to formation of AII and is unaltered by ACEI. Indeed, the effect of the non-ACE pathways and may reduce degradation of extracellular matrix leading to accumulation in the glomerulus [7, 16 ] . The may actually be exaggerated during treatment with ACEI as a result of high levels of AI and AT 1 receptor local effect of AT 1 -ra is dependent upon the distribution of AII receptor subtypes and considerable interup-regulation. It is not clear, however, if the non-ACE conversion of AI to AII is of clinical significance species variation in distribution has been demonstrated [17] . As a consequence of this the effects of AT 1 -ra although there is evidence that AII levels gradually rise with time after starting ACEI [10] . AT 1 -ra, by seen in animal studies, e.g. regression of left ventricular hypertrophy [18] , may be more difficult to demonstrate contrast, offer the possibility of 'total blockade' of the effects of AII at the AT 1 receptor that cannot be in humans as a result of the increased expression of AT 2 receptors in human myocardium [19, 17] . achieved by ACEI.
Limitations of AT 1
receptor blockade ACEI and AT 1 -ra alone or in combination?
AT 1 -ra should not be seen solely as an alternative to The results of prospective clinical trials evaluating the role of AT 1 -ra in renal disease are not yet available ACEI. Some patients do not achieve satisfactory blood pressure control (or renoprotection) on maximal doses and their efficacy, in this respect, remains unproven. Similarities in the mode of action (i.e. reduced AII-of ACEI and the combination may, therefore, allow further RAS blockade while overcoming some of the mediated activity) of AT 1 -ra and ACEI may suggest that their clinical effects will be comparable. There are concerns of using either agent in isolation. Additional RAS blockade has been confirmed by a further increase several reasons, however, why this may not be the case. In rats the beneficial effect of ACEI on renal in plasma renin levels [20] and seems not to have adverse clinical or biochemical effects. Animal models, haemodynamics is partly through bradykinin-mediated dilatation of the efferent arteriole [11] . This accounts however, have not found the combination to be better than either drug alone [21] . Further work is required for the fall in intraglomerular pressure (and the initial fall in glomerular filtration rate [GFR] and protein to study the expression of AT 2 receptor in disease states and to examine the possibility that some of the excretion [12]) after ACEI. In animal models AT 1 -ra do not appear to produce the fall in proteinuria that actions of AT 1 -ra may be due to AT 2 receptor stimulation. If the actions of AT1-ra were found to be is observed with ACEI although they have a similar effect on the attenuation of glomerulosclerosis [13] . In mediated partly by AT 2 receptor stimulation then the reduction in angiotensin II levels caused by ACEI may the absence of salt and water depletion, AT 1 -ra do not have this acute haemodynamic effect on the human be a possible explanation for the failure to demonstrate clinical synergy by concomitant use of both agents. kidney and do not produce an initial fall in GFR [14, 15] . A study of 13 patients did, however, observe a reduction in proteinuria with AT 1 -ra despite no Trials involving AT 1 receptor antagonists change in GFR [14] . The relative contribution of haemodynamic and non-haemodynamic mechanisms to the renoprotective effect of ACEI is not known, A recently published trial comparing AT 1 -ra and ACEI in patients with cardiac failure [ELITE] suggested that although the reduction in proteinuria appears to correl-AT 1 -ra are better tolerated [22] . There was also a in patients with progressive renal disease unless they are not tolerated. It is possible that AT 1 -ra may offer suggestion of superior efficacy of AT 1 -ra although this may be explained partly by a difference in compliance additional advantages in some patients or that synergy exists between the two agents, but this view will remain if ACEI were associated with increased side-effects. A study on the effect of AT 1 -ra on cardiovascular entirely speculative unless proper trials are conducted. Despite the results of the ELITE study [22] , the end-points is underway (Losartan Intervention for Endpoint Reduction-LIFE ) as are separate studies uncertainty regarding the use AT 1 -ra in cardiovascular disease mirrors that of renal disease. This issue is into the effects of Ibersartan (by the Collaborative Trial Group) and Ibersartan ( The RENAAL study) in obviously of relevance to the nephrologist in view of the spectrum of cardiac disease that accompanies delaying progression to end-stage renal failure in patients with type II diabetes and established nephro-chronic renal failure, such as left ventricular hypertrophy and cardiac failure, which provide multiple pathy. The Ibersartan and the Losartan studies will also evaluate the effect of AT 1 -ra on cardiovascular indications for manipulation of RAS. Despite their renoprotective effect, previous studies on ACEI [3, 4] events in a group at high risk of developing cardiovascular complications but they do not consider the effect have not shown an overall reduction in mortality and this issue needs to be addressed in addition to renoof preventing the progression from microalbuminuria to overt nephropathy, as was shown recently for ACEI protection in studies comparing AT 1 -ra and ACEI. [23] . Unless trials directly comparing AT1-ra to ACEI (±combined treatment) are carried out, the indication for AT 1 -ra over ACEI, with the exception of References intolerance to the latter, will remain elusive. 
